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Introduction {#sec0005}
============

Since 2012, Middle East respiratory syndrome coronavirus (MERS-CoV) has been reported worldwide, with a total of 2206 confirmed cases and 787 deaths in 27 countries ([@bib0185]). The spectrum of MERS-CoV infection ranges from a mild viral respiratory illness to a rapidly fatal pneumonia complicated by acute respiratory distress syndrome and acute renal failure ([@bib0055]), with a mortality rate of around 35--50% ([@bib0140], [@bib0195], [@bib0080]). No specific licensed antiviral treatment is currently available for MERS-CoV infection ([@bib0170]).

The most common clinical symptoms of MERS-CoV are fever, cough, and dyspnea. The positive detection rate is significantly higher in hospitalized patients with pneumonia compared to those with upper respiratory tract infections. These symptoms usually occur with a mean incubation period of 2--13 days. Comorbidities such as diabetes mellitus, cirrhosis, and others affecting the respiratory, renal, and cardiac systems have been shown to increase the severity of the illness ([@bib0195]). However, there is lack of specific clinical symptoms to distinguish MERS-CoV from other respiratory pathogens ([@bib0045]), making it imperative that early detection and laboratory identification of coronavirus infection is performed in suspected patients.

Three neighboring countries in Southeast Asia have reported MERS-CoV infections associated with a history of travel to the Middle East. In April 2014, a man in his mid-50s presented to the emergency ward of a public hospital in Malaysia. He had returned from a pilgrimage to Saudi Arabia 13 days earlier and was confirmed as the first MERS-CoV-infected case in the country ([@bib0165]). One year later, in February 2015, a 31-year-old woman in the Philippines was also diagnosed with MERS-CoV; she had a history of being resident in Saudi Arabia as a health worker ([@bib0175]). Four months later, MERS-CoV infection was also detected in an Omani citizen who had visited Thailand ([@bib0155]). MERS-CoV has never been reported in Indonesia, although thousands of pilgrims have visited the Middle East every year. Despite extensive efforts to screen for MERS-CoV in 28 197 returning pilgrims in Indonesia in 2015, the study did not identify any positive cases ([@bib0015]).

Prof. Dr. Sulianti Saroso Infectious Disease Hospital (IDH) in Indonesia is one of the referral hospitals for the evaluation of MERS-CoV in suspected patients. Up until 2018, none of the suspected patients returning from the Middle East were positive for MERS-CoV, although they were screened with relevant assays. In addition, none of the specimens were further evaluated to determine other etiologies that could tailor and improve patient management and reduce the inappropriate use of antibiotics.

The aim of this study was to identify emerging viral etiologies in suspected MERS-CoV patients admitted to IDH by screening bio-archived respiratory samples accumulated in 2015--2016.

Methods {#sec0010}
=======

Ethical approval {#sec0015}
----------------

The testing of archived specimens was approved by Prof. Dr. Sulianti Saroso IDH (ethical clearance number 54/VII.10/IX/2017) and the Eijkman Institute Research Ethics Commission (number 66, January 2017).

Patients, clinical data, and specimens {#sec0020}
--------------------------------------

Clinical specimens were collected from a total of 13 hospitalized patients with suspected MERS-CoV infection in Prof. Dr. Sulianti Saroso IDH from July 2015 to December 2016. The majority of patients presented with pneumonia and symptoms including fever (≥37.5 °C), dyspnea, and cough. All patients had a history of travel to the Middle East \<14 days prior to biological sampling. All biological specimens collected were sent to the bio-repository of Prof. Dr. Sulianti Saroso IDH for future research. The specimens (when available) including sputum, oropharyngeal swab, nasal swab, nasopharyngeal swab, and serum had tested negative for MERS-CoV by viral-specific PCR performed by the Indonesian Ministry of Health. The primers used in the PCR were designed to amplify the protein E, ORF1b, and ORF1a genes of MERS-CoV, as mentioned in the guidelines for MERS-CoV specimen sampling and laboratory examination of the Indonesian Ministry of Health. The specimens that had tested negative for MERS-CoV were further tested for additional respiratory viruses at the Eijkman Institute for Molecular Biology, Jakarta. Demographic data, risk factors, and clinical data were also analyzed.

Nucleic acid extraction and reverse transcription {#sec0025}
-------------------------------------------------

Total viral RNA was isolated from 140 μl of specimen (serum/respiratory swab) using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) following the manufacturer's protocol. Of a total of 60 μl of viral RNA, 4 μl was added to 1 μl random primer for complementary DNA (cDNA) synthesis using the GoScript Reverse Transcription System (Promega, Madison, WI, USA) to develop 20 μl of cDNA. The cDNA was then used as template for the detection of 12 viral families based on conventional PCR.

PCR assays for emerging viruses {#sec0030}
-------------------------------

Panels of a singleplex PCR assay were used for the detection of 12 taxa of viruses in respiratory specimens, including coronavirus, paramyxovirus, influenza virus, enterovirus, arenavirus, astrovirus, bocavirus, Nipah virus, adenovirus, hantavirus, herpesvirus, and respiratory syncytial virus. In addition, testing of serum for two families of arbovirus -- flavivirus and alphavirus -- was performed because of their endemicity in Indonesia.

All of the primers and positive controls used in the amplification reaction are based on the protocols from PREDICT USAID ([@bib0025]). The singleplex PCR reaction was performed in a thermal cycler ProFlex PCR system. A recombinant plasmid containing all sequences of PCR target or viral genetic materials from vaccines and isolates was used as a positive control in each PCR.

Gel visualization {#sec0035}
-----------------

Electrophoresis was done with 1% agarose gel in an electrophoresis chamber at 100 V for 30 min. Five microliters of PCR products were added to each agarose well, and a 100-bp DNA ladder (Invitrogen, Carlsbad, CA, USA) was used as a DNA size marker. Visualization of positive bands was performed using the Gel Imaging BioRad Gel Doc XR System and Quantity One 1-D Analysis Software.

Sequencing {#sec0040}
----------

Samples with positive viral amplicons were characterized by Sanger sequencing method after purification. Purification of PCR products was performed using the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol, followed by PCR sequencing and precipitation reaction before loading into an ABI 3130 sequencer. Sequencing results were analyzed using Geneious Software R8 version 8.1 and were compared with sequences in the GenBank database.

Results {#sec0045}
=======

During admission, 30 clinical specimens (seven oropharyngeal swabs, 11 nasal swabs, and 12 serum samples) were collected from 13 patients with pneumonia and risk factors associated with MERS-CoV infection, including history of travel to the Middle East \<14 days before illness. There was no history of contact with animals or sick people during their visit. Demographic and clinical characteristics of the patients are presented in [Table 1](#tbl0005){ref-type="table"} . The numbers of male and female patients were similar (male-to-female ratio, 7:6), and the median age of all patients was 61 years.Table 1Demographic characteristics and clinical presentation of suspected MERS-CoV patients in Prof. Dr. Sulianti Saroso Infectious Disease Hospital.Table 1DemographicsPatient IDPrevalence (Average)MER004 072015MER012 042016MER001 092016MER011 122016MER002 092016MER009 102015MER003 042016MER013 112015MER006 102015MER005 102015MER007 102015MER008 102015MER010 092016Age, years3266566034756537715961716157.5\
Median: 61 (32--75)SexFMMMFMFFMFFMMM: 7 (53.8%)Travel history to Middle East[a](#tblfn0005){ref-type="table-fn"}YesYesYesYesYesYesYesYesYesYesYesYesYes1 (100%)Purpose of travelUmrahUmrahUmrahUmrahHajjHajjUmrahHajjHajjHajjHajjHajjHajjDate of travelMay 2015Apr 2016Sept 2016Dec 2016Sept 2016Nov 2015Apr 2016Nov 2015Sept 2015Oct 2015Oct 2015Oct 2015Sept 2016Days of Hospitalization6NANA558735851025.8 daysDiagnosisPneumoniaPneumoniaPneumoniaPneumoniaPneumoniaPneumoniaPneumoniaPneumoniaPneumoniaPneumoniaPneumoniaPneumoniaPneumoniaCurb-65 severity score1000111010011OutcomeRecoveredRecoveredRecoveredRecoveredRecoveredRecoveredRecoveredRecoveredRecoveredRecoveredRecoveredRecoveredRecoveredClinical manifestations and laboratory investigationsFever (\>37.5 °C)YesYesYesYesYesYesYesYesYesYesYesYesYes13 (100%)CoughYesYesYesYesYesYesYesYesYesYesYesYesYes13 (100%)Chest painNoNoNoNoYesNoYesNoNoYesYesNoNo4 (30.8%)Difficulty breathingYesNoYesYesYesYesYesYesYesYesYesYesYes12 (92.3%)RonchiNoNoYesYesYesYesYesNoNoYesYesYesYes9 (69.2%)WheezingNoNoNoNoNoNoNoNoNoNoYesYesNo2 (15.4%)Respiratory rate (/min)2425242829282824242222273025.8Chest radiographyInfiltrationInfiltrationInfiltrationInfiltrationInfiltrationInfiltrationInfiltrationInfiltrationInfiltrationInfiltrationInfiltrationInfiltrationInfiltrationLeukocytes 1^st^ (/l)4.44.926.525.231.28.520.96.28.1NA7.732.811.915.6917Leukocytes 2^nd^ (/l)3.0NANA12.020.79.320.48.3NANA9.332.9NA14.4875Leukocytes 3^rd^ (/μl)5.1NANANA17.07.312.310.4NANA19.219.1NA12.9143Lymphocytes 1^st^ (%)4123131343131730NA1351215.6Lymphocytes 2^nd^ (%)NANANA2414514NANANA194NA13.3Antibiotics[b](#tblfn0010){ref-type="table-fn"}Cef, LevoCefMeroMeroMero, LevoMeroCefixMeroAziCefCef, LevoMero, LevoLevo[^1][^2][^3]

All patients were diagnosed with pneumonia, confirmed by chest X-ray and categorized in the low-severity pneumonia risk group based on the British Thoracic Society guidelines ([@bib0135]). The duration of hospital stay varied between 2 and 10 days, with an average duration of 5.8 days. The patients were placed in isolation rooms dedicated for airborne infectious diseases. All patients recovered fully.

A total of 18 respiratory clinical specimens that tested negative for MERS-CoV (by the Indonesian Ministry of Health) were retrospectively tested for 12 respiratory panels. In addition, 12 serum samples were tested for alphavirus and flavivirus to exclude the possibility of endemic viral infection. The coronavirus panel did not detect any MERS-CoV in any of the respiratory specimens, confirming the Indonesian Ministry of Health results. In this study, sequences of nine viral pathogens were detected in seven patients: four with single infections and three with multiple infections ([Table 2](#tbl0010){ref-type="table"} ). In patient ID MER004 072015, a co-infection of enterovirus and flavivirus was detected from nasal swab and serum, respectively. Nucleotide comparison of 357 nucleotides of the polyprotein gene using BLAST showed 99% similarity with enterovirus D68; for the flavivirus, 274 bases of the NS5 gene showed 98% similarity with dengue virus type 3. In patient ID MER002 092016, both herpesvirus and coronavirus were detected in the patient's oropharyngeal swab. Herpes simplex virus type 1 (HSV-1) was identified based on sequence matching of 400 bp through the online database (NCBI). Meanwhile, nucleotide comparison of 387 bases of the RNA-dependent RNA polymerase (RdRp) gene obtained from coronavirus showed 100% similarity with human coronavirus 229E (HCoV-229E). For patient ID MER009 102015, amplification of 400 bp untranslated region (UTR) gene of the enterovirus family and 243 bp M-gene region of influenza virus in a nasal swab revealed a rhinovirus A60 and influenza virus H1N1 (similarity 99% and 100%, respectively) co-infection. Single infections with rhinovirus C, influenza virus H3N2, human metapneumovirus (HMPV), and influenza virus H1N1 were identified in the respiratory swabs of patients with ID MER001 092016, MER007 102015, MER006 102015, and MER010 092016, respectively.Table 2Conventional PCR test results for viral agents from suspected MERS-CoV patients.Table 2Patient IDSpecimenVirus panelSequencing resultsCorona virusInfluenza virusEnterovirusPara myxovirusHerpes virusHenipavirusHanta virusArena virusAdenovirusAstrovirusRSVFlavivirusAlpha virusMER004 072015Oropharyngeal swab−−−−−−−−−−−NANANasal swab−−+−−−−−−−−NANAEnterovirus D68SerumNANANANANANANANANANANA+−Dengue 3 virusMER012 042016Oropharyngeal swab−−−−−−−−−−−NANANasal swab−−−−−−−−−−−NANASerumNANANANANANANANANANANA−−MER001 092016Nasal swab−−+−−−−−−−−NANARhinovirus CSerumNANANANANANANANANANANA−−MER011 122016Oropharyngeal swab−−−−−−−−−−−NANANasal swab−−−−−−−−−−−NANASerumNANANANANANANANANANANA−−MER002 092016Oropharyngeal swab-1−−−−+−−−−−−NANAHerpes simplex 1 virusOropharyngeal swab-2+−−−+−−−−−−NANACoronavirus 229E, herpes simplex 1 virusSerumNANANANANANANANANANANA−−MER009 102015Nasal swab−++−−−−−−−−−−Influenza virus H1N1, rhinovirus A60MER003 042016Serum−−−−−−−−−−−−−MER013 112015Serum−−−−−−−−−−−−−MER006 102015Nasal swab-1−−−−−−−−−−+NANAHuman metapneumovirusNasal swab-2−−−−−−−−−−+NANAHuman metapneumovirusSerumNANANANANANANANANANANA−−MER005 102015Nasal swab−−−−−−−−−−−−−SerumNANANANANANANANANANANA−−MER007 102015Nasal swab−+−−−−−−−−−−−Influenza virus H1N1SerumNANANANANANANANANANANA−−MER008 102015Oropharyngeal swab−−−−−−−−−−−NANANasal swab−−−−−−−−−−−NANASerumNANANANANANANANANANANA−−MER010 092016Oropharyngeal swab−+−−−−−−−−−NANAInfluenza virus H3N2Nasal swab−+−−−−−−−−−NANAInfluenza virus H3N2SerumNANANANANANANANANANANA−−[^4]

Discussion {#sec0050}
==========

Although patients with MERS-CoV usually present with an influenza-like illness, asymptomatic infection or cases with mild respiratory symptoms have also been reported ([@bib0125], [@bib0005]). In late infection, most of the MERS-CoV patients have been reported to develop pneumonia. Age, pneumonia, and a history of travel to the Middle East are important markers of MERS-CoV ([@bib0120]). Other factors increasing the risk of infection are male sex, contact with a camel or sick patient, diabetes mellitus, severe illness, low white blood cell count, low alanine aminotransferase, and high aspartate aminotransferase ([@bib0010]). The coronavirus family panel used in this study has been validated to detect MERS-CoV ([@bib0030]). However, no MERS-CoV was detected, which could be due to the small sample size. Although the severity of pneumonia of all suspected MERS-CoV patients was categorized as low risk based on the British Thoracic Society guidelines ([@bib0120]), they would be categorized as severe pneumonia cases under the Korean guidelines, due to lung infiltrations on chest X-ray and the requirement for oxygen therapy ([@bib0150]).

A co-infection of enterovirus D68 and dengue virus type 3 was identified in patient ID MER004 072015. She was 32 years old and presented with fever, cough, wheezing, and difficulty breathing. In adults, enterovirus D68 is rarely reported as a cause of severe illness. However, the virus has attracted international attention since it was associated with community-acquired pneumonia in children in China and Italy ([@bib0070], [@bib0040], [@bib0205], [@bib0075]). It is possible that the pneumonia in this case was due to the enterovirus D68 infection; further phylogenetic analysis is needed to compare this strain with other enterovirus D68. In 2014, a large outbreak of enterovirus D68 was confirmed in 49 states in the USA involving at least 1153 cases and 14 deaths. Recent reports have shown a possible association between enterovirus D68 and acute flaccid paralysis ([@bib0130], [@bib0065]). However, no sign of neurological disorder was observed in this patient.

Patient ID MER002 092016 suffered from pneumonia, sepsis, hypoalbuminemia, and leukocytosis (26.5 × 10^9^/l). This patient was co-infected with HCoV-229E and HSV-1. With the exception of varicella zoster and human herpesvirus 6, human herpesviruses are rarely associated with pneumonitis ([@bib0060], [@bib0100]). However, one case study reported a lower respiratory tract infection caused by HSV-1 in a 72-year-old man with underlying disease ([@bib0115]). HSV-1 is very infectious and highly prevalent in the world, with more than 60% of the population exposed to this virus in 2012 ([@bib0110]). It usually causes orolabial ulcers that can lead to neurotrophic complications with lifelong potential for symptomatic or asymptomatic viral shedding episodes ([@bib0110], [@bib0090]). HCoV-229E is one type of coronavirus commonly infecting humans. An epidemiological study conducted in adults with community-acquired pneumonia confirmed that four human coronaviruses (HCoV-229E, HCoV-NL-63, HCoV-HKU1, and HCoV-OC43) accounted for 0.6--2.5% of pneumonia cases ([@bib0200]). In this case, HCoV-229E was the most likely cause of pneumonia.

In patient MER001 092016, rhinovirus C genetic material was detected from a nasal swab. Rhinoviruses have often been associated with pneumonia in adults. Rhinovirus C was recently discovered; this is not as well characterized as rhinoviruses A and B ([@bib0050]). There is controversy regarding the clinical severity of rhinovirus C infection ([@bib0050], [@bib0035]). The virus can induce diverse clinical outcomes, with factors including species and type-specific differences as determinants of severity ([@bib0200], [@bib0050], [@bib0035], [@bib0020]). Globally, rhinovirus C has been linked to lower respiratory tract infections such as bronchitis, bronchiolitis, and pneumonia, especially when there is co-infection with other viruses, such as bocavirus and influenza virus ([@bib0105]). In Indonesia, data on rhinovirus C are limited, with only one report related to myocarditis ([@bib0190]).

Influenza virus H1N1 was detected in patients MER009 102015, MER007 102015, and MER010 092016. In addition, patient MER009 102015 was co-infected with rhinovirus A60. Influenza virus H1N1 is known to cause a serious infection that can lead to the development of pneumonia and death if it progresses to acute respiratory distress syndrome. In the present study, HMPV was detected from a nasal swab of a 71-year-old patient with pneumonia. HMPV is one of the most significant causes of upper and lower respiratory tract infections in children and the elderly, especially the immunocompromised and those with underlying respiratory conditions ([@bib0145], [@bib0180], [@bib0085]). Two genotypes of HMPV have been identified, which can be classified into five lineages, A1, A2a, A2b, B1, and B2. However, their association with disease severity remains unclear ([@bib0095]). There is only a single report on HMPV from Indonesia, documenting the association of HMPV lineage A1 and A2 with asthma exacerbations and pneumonia, indicating that HMPV should be screened in those with chronic and severe respiratory infections ([@bib0160]).

This study, together with that of Amin et al., strengthens the conclusion that Indonesia remained MERS-CoV-free, at least up until 2015--2016. There are some limitations to this study, such as the weakness of statistical power due to the lack of information on the total number of subjects screened and the small number of patients involved in this study. Secondly, although the specimens were mostly obtained during the acute febrile phase, beneficial for molecular screening, serology was not performed for a more comprehensive investigative approach. Thirdly, the detection of viral pathogens in swabs did not imply causality, as additional viral and bacterial panels need to be evaluated.

In conclusion, the sequences of nine viral pathogens were detected in samples from seven suspected MERS-CoV patients hospitalized in Prof. Dr. Sulianti Saroso IDH, Indonesia. Etiological agents detected in the patient samples were enterovirus D68, dengue virus type 3, rhinovirus C, HCoV-229E, HSV-1, influenza virus H1N1, influenza virus H3N2, HMPV, and rhinovirus A60. This study also confirmed that there was no MERS-CoV genetic material detected from these 13 patients. Along with results reported by Amin et al., we confirmed that Indonesia remained MERS-CoV-free in 2015--2016. In conclusion, the early detection and identification of the etiological agent is crucial for the containment of MERS-CoV in those with a history of travel to the Middle East, and if results are negative, testing should be performed for additional pathogens to improve patient management.
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[^1]: MERS-CoV, Middle East respiratory syndrome coronavirus; F, female; M, male; NA, not available.

[^2]: History of travel to Middle East \<14 days before admission to the hospital.

[^3]: Cef, ceftriaxone, Levo, levofloxacin, Mero, meropenem, Azi, azithromycin, Cefix, cefixime.

[^4]: NA, not available.
